Metastatic NRG1-Fusion Lung Cancer Responding to Long-Term Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: CD74-NRG1 fusion

Metastatic Site: lungs

As of February 2020, she remained on afatinib 30 mg daily with an ongoing partial response after 27 months.

PubMed CentralRead more →

Recurrent NRG1-Fusion Lung Cancer After Surgery and Immunotherapy

Patient Info: Anonymized, Male, 60s | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion

He chose no further treatment after rapid progression on afatinib and died shortly afterward in hospice.

PubMed CentralRead more →

Stage IV Mucinous Lung Cancer Treated With Afatinib and Surgery

Patient Info: Anonymized, Female, 40s | Stage IV

Biomarkers: CD74-NRG1 fusion; ALK/ROS1/EGFR/BRAF/KRAS/MET/HER2 wild type; PD-L1 initially not expressed and later 0%-20%

Metastatic Site: bilateral lungs|bone|right adrenal gland

She was alive and receiving treatment after bone and right-adrenal progression at the latest follow-up.

PubMed CentralRead more →

Recurrent Mucinous Lung Cancer With Dose-Dependent Afatinib Responses

Patient Info: Anonymized, Female, Under 40 | Stage Metastatic/Advanced

Biomarkers: SDC4-NRG1 fusion; PD-L1 not expressed; low tumor mutation burden

Metastatic Site: bilateral lungs

She had progressive lung disease after several targeted-treatment attempts and was receiving paclitaxel with bevacizumab as of February 2020.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Saila's Patient Story

Patient Info: Saila Hanninen, Under 40 | Stage IV

Biomarkers: EGFR mutation

After progression on earlier EGFR-directed treatment and other therapies, Saila began chemotherapy and her cancer was stable at the time of the story.

Dana-FarberRead more →

Small Cell Lung Cancer With Unusual Colon Metastases After Afatinib

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: EGFR exon 19 deletion

Metastatic Site: liver|adrenal glands|bone|brain|ascending…

The cancer progressed after an initial response to afatinib, with new brain and colon metastases. She died from respiratory failure on August 1, 2016.

PubMed CentralRead more →

Long response to afatinib in EGFR-mutated lung cancer

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: EGFR L861Q mutation; EGFR G719X mutation

Metastatic Site: multiple bilateral ribs

CT at 30 months showed no recurrence, and he remained well 32 months after starting afatinib.

PubMed CentralRead more →

ROS1-positive lung adenocarcinoma presenting with cancer spread across the abdomen

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ROS1 rearrangement-positive; high PD-L1 expression.

Metastatic Site: peritoneum and omentum; pleura

Crizotinib relieved his respiratory and abdominal symptoms, and six-month imaging showed no residual disease or progression while treatment continued.

PubMed CentralRead more →

Stage IV Non-Small Cell Lung Cancer: Tomma's Patient Story

Patient Info: Tomma Hargraves, Female | Stage IV

Metastatic Site: brain

After a later brain and lymph-node relapse was brought under control, Tomma had no further cancer treatment and remained active in survivorship advocacy. She died on September 7, 2023.

Tomma Hargraves: Choosing to Help Other Patients after Surviving Lung Cancer

Patient Info: Tomma Hargraves | Stage IV

Metastatic Site: brain

After treatment and a later recurrence, Tomma went many years without further cancer treatment and became a patient navigator and advocate. She died on September 7, 2023.

Stage IV EGFR-mutated lung cancer responding to osimertinib despite new lung opacities

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R mutation; EGFR T790M mutation

Metastatic Site: bilateral lungs

Over the following year on osimertinib, imaging showed an excellent tumour response with gradual improvement of the lung opacities and sustained clinical improvement.

PubMed CentralRead more →

Osimertinib rechallenge after severe pneumonitis in Stage IV lung cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR exon 19 deletion; acquired EGFR T790M mutation

Metastatic Site: pleura, liver, bone, leptomeninges

She initially regained a significant response after osimertinib rechallenge without recurrent pneumonitis, but developed progressive leptomeningeal disease after 11 months.

PubMed CentralRead more →

Erlotinib-related uveitis during treatment for stage IV EGFR-mutated lung cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR L858R mutation-positive.

A partial response to erlotinib was maintained at six months, while the uveitis resolved and did not recur after treatment resumed at a lower dose.

PubMed CentralRead more →

Stage IV RET Non-Small Cell Lung Cancer: Sara's Patient Story

Patient Info: Sara Whitlock, Female, 40s | Stage IV

Biomarkers: RET fusion-positive NSCLC

Metastatic Site: Brain; abdomen; bowel

As of November 2019, Sara had Stage IV RET fusion-positive NSCLC with a long-term response and no signs of cancer while taking selpercatinib/LOXO-292 on a clinical trial, with ongoing monthly follow-up.

Cleveland ClinicRead more →

Stage IV ALK Non-Small Cell Lung Cancer: James's Patient Story

Patient Info: James “Rocky” Lagno, Male | Stage IV

Biomarkers: ALK-positive

Metastatic Site: brain

After starting ceritinib through compassionate use, Rocky reported stable disease from the middle of 2013 with quality of life close to his pre-diagnosis level, while recognizing that he was not in remission or cancer-free.

Stage IV EGFR Non-Small Cell Lung Cancer: Ginger's Patient Story

Patient Info: Ginger Tam, Female | Stage IV

Biomarkers: EGFR mutation

Ginger lived for more than 5 years with metastatic lung cancer while receiving multiple research-driven treatments. She died on February 10, 2018.

Lung Cancer Metastasis to the Iris Treated With Bevacizumab

Patient Info: Anonymized, Male, 60s | Stage IV

Metastatic Site: right iris

The iris lesion and eye symptoms improved after bevacizumab, but he later died from systemic complications of metastatic lung cancer.

PubMed CentralRead more →

Osimertinib Improved Spinal Cord Metastases in Long-Standing Lung Cancer

Patient Info: Anonymized, Male, 50s | Stage IV

Biomarkers: Initial surgical specimen: no detected EGFR mutation and ALK-negative. Later pleural-fluid tumor: acquired EGFR T790M mutation with no other detected EGFR mutation.

Metastatic Site: cervical and mediastinal lymph nodes; bone; brain;…

Osimertinib improved neurologic function and kept the lung cancer stable for 14 months; he later died from bacterial pneumonia.

PubMed CentralRead more →

Hormone Problems During Nivolumab Treatment for Advanced Lung Cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR/ALK/ROS1/BRAF wild type

Metastatic Site: abdominal wall|brain

She was living with Stage IVA lung cancer after about 1 year of nivolumab. Thyroid levels normalized after levothyroxine adjustment, and continued endocrine monitoring was planned for treatment-related pituitary dysfunction.

PubMed CentralRead more →

Stage IV ALK Lung Adenocarcinoma: Amanda's Survivor Story

Patient Info: Amanda Nerstad, Under 40 | Stage IV

Biomarkers: ALK-positive

She achieved a complete metabolic response on alectinib and had shown no evidence of disease since November 2017 while continuing treatment.

MD AndersonRead more →

EGFR-Mutated Stage IV Lung Adenocarcinoma With Painful Finger Lesions During Osimertinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR-mutated; EGFR T790M-positive at relapse

She remained on active osimertinib treatment; the finger lesions persisted but were controlled with colloidal oatmeal.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Molly's Patient Story

Patient Info: Molly Golbon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Left hip; right shoulder; brain

Molly had a strong early response to Tarceva for Stage IV EGFR-mutated lung cancer, with about 50% tumor shrinkage after 2 months and metastatic disease described as almost undetectable; no later remission/NED status is provided in this record.

The Patient StoryRead more →

Autoimmune hemolytic anemia after 39 cycles of nivolumab for metastatic lung cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

While nivolumab remained on hold, his lung cancer was stable on imaging and clinically, and hemoglobin had recovered to 14.6 g/dL about 4 months after high-dose prednisone and rituximab began.

PubMed CentralRead more →

Finding Happiness Despite Stage IV Lung Cancer

Patient Info: Anonymized, 50s | Stage IV

More than a year after diagnosis, she remained in treatment for Stage IV lung cancer, with some therapies losing effectiveness as the cancer developed resistance.

Dana-FarberRead more →